Global Market Footprint Vaxxinova operates in more than 75 countries with production and R&D facilities across 12 countries, enabling multi-region sales opportunities and cross-selling of vaccines and diagnostic services for livestock, poultry, and aquaculture. The recent Labovet acquisition in Brazil strengthens Latin American penetration and provides regional distribution benefits that can be leveraged for new accounts.

Poultry Growth Focus A clear emphasis on poultry is evidenced by the appointment of a Key Account Manager for Poultry in Poland and participation in major poultry industry events in the US and Europe. This creates opportunities to target poultry integrators, hatcheries, and producers with vaccines, biosecurity diagnostics, and disease management programs across Europe, North America, and Asia.

R&D Driven Innovation Vaxxinova highlights strong R&D investment within the EW Group, positioning a pipeline of innovative vaccines and diagnostic solutions to address current and future animal health needs. BD teams can position early access programs, trials, and co-development opportunities to lock in strategic customers ahead of competitors.

Latin America Expansion Strategic expansion in Latin America, including the Labovet acquisition in Brazil, expands local presence and distribution capabilities, enabling channel partnerships and broader market access across the region.

Industry Engagement Active participation in industry events (VIV Europe, Poultry Days, and the International Production & Processing Expo) indicates a robust lead-generation channel. Sales teams should leverage these events to secure trials, demonstrations, and executive briefings, and to identify regional distributors and strategic accounts for near-term revenue opportunities.